Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Diabetic Retinopathy01:27

Diabetic Retinopathy

66
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
66

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustainability awareness among European dry eye disease specialists.

European journal of ophthalmology·2026
Same author

Neuroinflammation and mononuclear phagocytes in glaucoma: From ocular pathogenesis to central visual pathway involvement - A comprehensive review.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis.

Ophthalmology and therapy·2026
Same author

Twelve-month outcomes after open bleb revision for Preserflo<sup>®</sup> microshunt bleb failure in refractory glaucoma patients.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Efficacy and Safety of the Preserflo<sup>®</sup> Microshunt as a Standalone Procedure Versus Its Combination with Phacoemulsification.

Journal of clinical medicine·2026
Same author

A Systematic and Narrative Review of Safety and Complications in Minimally Invasive Glaucoma Surgery (MIGS) Between 2014-2024 [Response to Letter].

Clinical ophthalmology (Auckland, N.Z.)·2026

Related Experiment Video

Updated: May 7, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.3K

[Glaucoma today: detection and therapeutic progress].

Christophe Baudouin1, Alexandre Denoyer, William Rostène

  • 1Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, 28 rue de Charenton, 75012 Paris, France - Institut de la Vision, Université Pierre et Marie Curie, INSERM UMR S968, CNRS UMR 7210, 17 rue Moreau, 75012 Paris, France.

Biologie Aujourd'Hui
|October 10, 2013
PubMed
Summary

Glaucoma treatments face challenges from long-term preservative toxicity, particularly benzalkonium chloride. New research explores targeting chemokines like CXCL12 to treat glaucoma at its onset, offering safer, more effective therapies.

More Related Videos

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

12.7K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.7K

Related Experiment Videos

Last Updated: May 7, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.3K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

12.7K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.7K

Area of Science:

  • Ophthalmology
  • Neuroscience

Context:

  • Glaucoma is the second leading cause of blindness globally, characterized by optic neuropathy often linked to elevated intraocular pressure.
  • Current treatments primarily focus on managing intraocular pressure, with topical medications being the first-line therapy, often requiring lifelong use.

Purpose:

  • To review the limitations of current glaucoma treatments, including side effects from preservatives like benzalkonium chloride.
  • To explore novel therapeutic strategies targeting the underlying mechanisms of glaucoma, such as chemokine pathways.

Summary:

  • Long-term use of topical glaucoma medications can lead to ocular surface disease due to preservatives like benzalkonium chloride.
  • Emerging research highlights the role of chemokines, such as CXCL12, in trabecular meshwork degeneration.
  • Blocking the CXCL12 receptor has shown potential in reducing intraocular pressure and preventing trabecular cell damage.

Impact:

  • Development of preservative-free glaucoma therapies to improve patient quality of life and compliance.
  • Innovative treatments targeting disease mechanisms, potentially offering earlier intervention and better outcomes for glaucoma patients.